AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9432479 — intervention group
Group type: COMPARATOR
Intervention: Both groups (30 and 50 micrograms)
Number of subjects: 0
Study 8101254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual oestradiol‐17 beta (1 mg)
Number of subjects: 11
Study 8101254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3305189 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, cytoxan, and prednisone (VCP)
Number of subjects: 244
Study 3305189 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with vincristine, rubidazone, araC, and prednisone (VRAP)
Number of subjects: 244
Study 3305189 — intervention group
Group type: EXPERIMENTAL
Intervention: Postremission consolidation using adriamycin, araC, and asparaginase (AAA)
Number of subjects: 244
Study 3305189 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 244
Study 31709920 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐YA
Number of subjects: 74
Study 31709920 — intervention group
Group type: EXPERIMENTAL
Intervention: FT‐YA
Number of subjects: 74
Study 29248397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back mobility exercises from Pilates
Number of subjects: 28
Study 29248397 — intervention group
Group type: COMPARATOR
Intervention: Low back stability exercises from Pilates
Number of subjects: 28
Study 27260862 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Citrate (Kcitrate)
Number of subjects: 11
Study 27260862 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Chloride (KCl)
Number of subjects: 11
Study 27260862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 25222606 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study 25222606 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 20
Study 25222606 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing
Number of subjects: 20
Study 23439351 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 96
Study 23439351 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 96
Study 21477047 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-based treatment (RBT)
Number of subjects: 89
Study 21477047 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 89
Study 18479404 — intervention group
Group type: COMPARATOR
Intervention: Web-based questionnaire (n=271)
Number of subjects: 532
Study 18479404 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil questionnaire (n=261)
Number of subjects: 532
Study 15858160 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity of the dorsolateral, ventrolateral and medial prefrontal cortices during deception (both types: pretending to know and pretending not to know)
Number of subjects: 0
Study 15858160 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity of the anterior cingulate cortex (ACC) during deception (specifically pretending not to know)
Number of subjects: 0
Study 15858160 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) increase in the ACC
Number of subjects: 0
Study 12633783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 265
Study 12633783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 10686191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 273
Study 10686191 — intervention group
Group type: COMPARATOR
Intervention: Buserelin
Number of subjects: 273
Study 9315991 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg quazepam
Number of subjects: 30
Study 9315991 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg quazepam
Number of subjects: 30
Study 9315991 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg quazepam and 15 mg quazepam
Number of subjects: 30
Study 9315991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7680764 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 899
Study 7680764 — intervention group
Group type: COMPARATOR
Intervention: MACOP-B
Number of subjects: 899
Study 7680764 — intervention group
Group type: EXPERIMENTAL
Intervention: m-BACOD
Number of subjects: 899
Study 7680764 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 899
Study 7680764 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 899
Study 7680764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal toxic reactions
Number of subjects: 899
Study 3050179 — intervention group
Group type: EXPERIMENTAL
Intervention: Journal club
Number of subjects: 44
Study 3050179 — intervention group
Group type: COMPARATOR
Intervention: Control seminar series
Number of subjects: 44
Study 31907248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-initiated prompt to ask a QOL question: 'What things are you unable to do because of your health problems today?'
Number of subjects: 60
Study 31907248 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prompting to ask QOL questions.
Number of subjects: 60
Study 29303859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone xenograft granules (0.25 to 1 mm of size, 1 mL/vial) with a resorbable pericardium membrane
Number of subjects: 20
Study 29303859 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated extraction socket)
Number of subjects: 20
Study 29303859 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 20
Study 27607865 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 1767
Study 27607865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study 25397817 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP+TAU
Number of subjects: 146
Study 25397817 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 146
Study 23719147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment EEG features
Number of subjects: 446
Study 23719147 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortest seizure duration
Number of subjects: 446
Study 20962560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose breath test (LBT)
Number of subjects: 76
Study 19363850 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide combination
Number of subjects: 11140
Study 19363850 — intervention group
Group type: COMPARATOR
Intervention: Background antihypertensive therapies
Number of subjects: 11140
Study 17203670 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy interventions (personal care, information, prescription of assistive devices, planning of discharge, reporting to primary care or community care)
Number of subjects: 41
Study 17203670 — intervention group
Group type: COMPARATOR
Intervention: No occupational therapy interventions (control group)
Number of subjects: 41
Study 14601526 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) in combination with rituximab (Rituxan) for non-Hodgkin's lymphoma
Number of subjects: 0
Study 14601526 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) as a vaccine adjuvant
Number of subjects: 0
Study 14601526 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG‐7909 (ProMune) for melanoma
Number of subjects: 0
Study 10230184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 10230184 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 10230184 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 8953207 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg
Number of subjects: 129
Study 8953207 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 129
Study 8953207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 1752712 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (650 mg ferrous sulfate; 130 mg elemental iron)
Number of subjects: 10
Study 1752712 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 7039147 — intervention group
Group type: EXPERIMENTAL
Intervention: Feprazone 600 mg
Number of subjects: 40
Study 7039147 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 750 mg
Number of subjects: 40
Study 31093797 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement with photobiomodulation (PBM)
Number of subjects: 19
Study 31093797 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement only (control group)
Number of subjects: 19
Study 28283279 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐ionto CL
Number of subjects: 25
Study 28283279 — intervention group
Group type: COMPARATOR
Intervention: Standard CL
Number of subjects: 25
Study 25838001 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 23
Study 25838001 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 23
Study 25838001 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence (not using illicit opiates on top of prescribed opiates)
Number of subjects: 23
Study 23846250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant) administration (30 mg/cm height, up to three doses)
Number of subjects: 110
Study 23846250 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 110
Study 23846250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (calfactant) administration
Number of subjects: 110
Study 20889533 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused intervention
Number of subjects: 94
Study 20889533 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented intervention
Number of subjects: 94
Study 19228095 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 10
Study 19228095 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 10
Study 19228095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PDT and SRP
Number of subjects: 10
Study 17203469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine pretreatment with loading dose (group 1)
Number of subjects: 2040
Study 17203469 — intervention group
Group type: COMPARATOR
Intervention: Thienopyridine pretreatment without loading dose (group 2)
Number of subjects: 2040
Study 17203469 — intervention group
Group type: COMPARATOR
Intervention: No thienopyridine pretreatment (group 3)
Number of subjects: 2040
Study 17203469 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (GP IIb/IIIa inhibitor)
Number of subjects: 2040
Study 17203469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine pretreatment with eptifibatide
Number of subjects: 2040
Study 15013031 — intervention group
Group type: EXPERIMENTAL
Intervention: Flesinoxan
Number of subjects: 6
Study 15013031 — intervention group
Group type: COMPARATOR
Intervention: Pindolol (30 mg p.o.)
Number of subjects: 6
Study 15013031 — intervention group
Group type: COMPARATOR
Intervention: Ritanserin (10 mg p.o.)
Number of subjects: 6
Study 11329832 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation of positive outcomes
Number of subjects: 57
Study 11329832 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of negative outcomes
Number of subjects: 57
Study 11329832 — intervention group
Group type: COMPARATOR
Intervention: Allocation of negative outcomes
Number of subjects: 57
Study 11329832 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of positive outcomes
Number of subjects: 57
Study 9141898 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b, 5 megaunits tiw for 8 weeks, then reduced to 3 megaunits up to 9 months (group A)
Number of subjects: 106
Study 9141898 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b, 5 megaunits tiw for 16 weeks, then reduced to 3 megaunits up to 9 months (group B)
Number of subjects: 106
Study 7950223 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian Pi Ling (JPL) tablet with retention‐enema of Radix Sophorae Flavescentis and Flos Sophora (RSF‐FS) decoction
Number of subjects: 153
Study 7950223 — intervention group
Group type: EXPERIMENTAL
Intervention: salicylazosulfapyridine (SASP) and retention‐enema of dexamethasone
Number of subjects: 153
Study 7950223 — intervention group
Group type: COMPARATOR
Intervention: Placebo and retention‐enema of decoction as that in group I
Number of subjects: 153
Study 3035479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 30
Study 3035479 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 30
Study 29542812 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness meditation (MM) practice + control task
Number of subjects: 120
Study 29542812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) practice + values clarification (VC) task
Number of subjects: 120
Study 28634365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin) in patients with SBP ≥ 140 mmHg
Number of subjects: 0
Study 28634365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin in patients with DBP ≥ 90 mmHg
Number of subjects: 0
Study 28634365 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone in patients with SBP < 140 mmHg or DBP < 90 mmHg
Number of subjects: 0
Study 28634365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 0
Study 26132887 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-regulation activities (goal-setting and self-monitoring)
Number of subjects: 0
Study 26132887 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated goal-setting and monitoring
Number of subjects: 0
Study 26132887 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated self-monitoring
Number of subjects: 0
Study 23562341 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA), treated twice a day for 6 weeks
Number of subjects: 32
Study 23562341 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treated twice a day for 6 weeks
Number of subjects: 32
Study 21941046 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional Cash Incentive (ACI) scheme within the CCT scheme
Number of subjects: 0
Study 21941046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACI scheme)
Number of subjects: 0
Study 18476292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy (ART; drug conservation [DC] group])
Number of subjects: 477
Study 18476292 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART (viral suppression [VS] group)
Number of subjects: 477
Study 16550574 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) combined with hepatic arterial infusion (HAI) chemotherapy (FUDR) for 6 months
Number of subjects: 21
Study 12527158 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and self-management intervention consisting of two 2-hour group sessions followed by 1-2 individual sessions by a nurse and a physiotherapist.
Number of subjects: 78
Study 12527158 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 78
Study 11177273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (platinum derivative)
Number of subjects: 0
Study 8634735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intramuscular (IM) ceftriaxone sodium
Number of subjects: 648
Study 8634735 — intervention group
Group type: COMPARATOR
Intervention: 10-day oral amoxicillin and clavulanate potassium
Number of subjects: 648
Study 2049686 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol monotherapy
Number of subjects: 24
Study 2049686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem monotherapy
Number of subjects: 24
Study 2049686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-nitrate combination
Number of subjects: 24
Study 2049686 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate added to either monotherapy
Number of subjects: 24
Study 2049686 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide ventriculography
Number of subjects: 24
Study 6840166 — intervention group
Group type: EXPERIMENTAL
Intervention: Two well recognised treatment regimes
Number of subjects: 138
Study 31486728 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-guided, self-management ACP approach including a Five Wishes form
Number of subjects: 800
Study 31486728 — intervention group
Group type: COMPARATOR
Intervention: Structured ACP with Respecting Choices First Steps
Number of subjects: 800
Study 31486728 — intervention group
Group type: EXPERIMENTAL
Intervention: After-death interviews with surrogates of patients who die during the study
Number of subjects: 800
Study 28654558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecs II block under general anesthesia (group P)
Number of subjects: 64
Study 28654558 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (group G)
Number of subjects: 64
Study 26621498 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 27
Study 26621498 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 27
Study 24953541 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Number of subjects: 40
Study 22672578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) treatment plus compression therapy (CT)
Number of subjects: 0
Study 22672578 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy (CT) alone
Number of subjects: 0
Study 20382711 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels > 800 pg/mL
Number of subjects: 195
Study 20382711 — intervention group
Group type: COMPARATOR
Intervention: Serum VEGF-D levels < 600 pg/mL
Number of subjects: 195
Study 20382711 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels in S-LAM
Number of subjects: 195
Study 20382711 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF-D levels in TSC-LAM
Number of subjects: 195
Study 20382711 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-D level > 600 pg/mL
Number of subjects: 195
Study 20382711 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for VEGF-D
Number of subjects: 195
Study 18609485 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific lesions in patients with acute myeloid leukemia (AML)
Number of subjects: 180
Study 18609485 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific lesions in patients with acute lymphocytic leukemia (ALL)
Number of subjects: 180
Study 18609485 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of specific lesions in AML and ALL groups
Number of subjects: 180
Study 18609485 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of specific orbital or ocular lesions
Number of subjects: 180
Study 16243150 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept for 24 weeks
Number of subjects: 100
Study 16243150 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by etanercept for 12 weeks
Number of subjects: 100
Study 12088968 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB with a Sprotte needle (24-gauge)
Number of subjects: 60
Study 12088968 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB with a Quincke needle (25-gauge)
Number of subjects: 60
Study 12088968 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural block (control group)
Number of subjects: 60
Study 9820884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-containing formulations (disodium monofluorophosphate and sodium fluoride)
Number of subjects: 7
Study 9820884 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 7
Study 9638198 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers handling X-ray equipment
Number of subjects: 44
Study 9638198 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers handling X-ray equipment (over five years)
Number of subjects: 44
Study 9638198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 2654256 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cat-hair and dander extract (11 patients)
Number of subjects: 22
Study 186090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.3 mg/kg)
Number of subjects: 5
Study 186090 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (1.0 mg/kg)
Number of subjects: 5
Study 186090 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (vasoconstrictor doses) with propranolol or practolol
Number of subjects: 5
Study 186090 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion
Number of subjects: 5
Study 31912376 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention (details not specified)
Number of subjects: 155
Study 30545435 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach via a mailed letter regarding alprazolam use reduction
Number of subjects: 326
Study 30545435 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 326
Study 30545435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients who called the clinical pharmacist (CP)
Number of subjects: 326
Study 30545435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients who did not call the CP
Number of subjects: 326
Study 28886734 — intervention group
Group type: EXPERIMENTAL
Intervention: Healingo Fit intervention (pedometer-based and gamified)
Number of subjects: 144
Study 28886734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study 23392651 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal hint exposure (1-min movie)
Number of subjects: 509
Study 20841418 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 25 μg/min
Number of subjects: 75
Study 20841418 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 50 μg/min
Number of subjects: 75